SCHEMBL3923211

SCHEMBL3923211

CCC(CC)c1cc(C)nn2c(-c3sc(-c4ccc(F)cc4)cc3Cl)c(C)nc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 3/20 0.63
CRHR2 Q13324 1/20 0.52
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SMPD3 Q9NY59 2/20 0.35
TSPO P30536 1/20 0.34
POLB P06746 2/20 0.33
AR P10275 1/20 0.32
STAT1 P42224 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CASP3 P42574 1/20 0.31
BLM P54132 1/20 0.31
NCOA1 Q15788 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926806 0.90 CRHR1 (0.65) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3920629 0.89 CRHR1 (0.54) CRHR1CRHR2SMPD3
SCHEMBL3931894 0.86 CRHR1 (0.54) CRHR1CRHR2
SCHEMBL3920559 0.86 CRHR1 (0.52) CRHR1CRHR2RAB9AKDM4EMAPT
SCHEMBL3923468 0.85 CRHR1 (0.53) CRHR1CRHR2
SCHEMBL3933908 0.84 CRHR1 (0.55) CRHR1CRHR2
SCHEMBL3928328 0.83 CRHR1 (0.66) CRHR1CRHR2MEN1KMT2ARAB9A
SCHEMBL3922576 0.82 CRHR1 (0.54) CRHR1CRHR2
SCHEMBL3921234 0.82 CRHR1 (0.62) CRHR1CRHR2KDM4EMAPTSMPD3
SCHEMBL3926284 0.82 CRHR1 (0.53) CRHR1CRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612067-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-11-03 US disclosed
US-7612067-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-11-03 US disclosed
US-7612067-B2 Imidazopyridazine compounds ELI LILLY AND COMPANY (US) 2009-11-03 US disclosed
EP-1869049-B1 IMIDAZOPYRIDAZINE COMPOUNDS LILLY CO ELI (US) 2009-03-04 EP disclosed
US-20080113978-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-05-15 US disclosed
US-20080113978-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-05-15 US disclosed
US-20080113978-A1 Imidazopyridazine Compounds ELI LILLY AND COMPANY 2008-05-15 US disclosed
EP-1869049-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2007-12-26 EP disclosed
WO-2006102194-A1 IMIDAZOPYRIDAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113978-A1 Imidazopyridazine Compounds CRHR1, CRH, CRHR2 CRHR1 1/4885CRHR2 3/4885MEN1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.